Completely agree with that assessment jvmho, the Company’s been in stealth mode for at least 2 years, and I’ll trust that Dr M and the BOD have their (competitive) reasons.
Also telling were the hiring of Dr Walter Kauffman as our CMO this year, and the display of confidence by Dr Missling when explaining Anavex’s moa/efficacy during the March 2019 ROTH conference panel “Alzheimer’s: Beyond the Rise and Fall of Amyloid”.
The market forces (BP giants and their entrenched tau/amyloid plaque scientists/media/Hedge funds/FUD agents) are by now aware of Anavex and our consortium/Hampel ties and PM leadership & our expanding/extending CNS trials, and I’m convinced that their game plan has been/is to keep Anavex marginalized for as long as possible.
With compounds that are purported to prompt the body to heal itself and self-correct (as well as modulate autophagy) & thereby potentially treat a WIDE range of various CNS afflictions and diseases (reference our pipeline) https://www.anavex.com/#!/aboutus it’s not difficult to understand why our small Company would be quite disruptive and thereby threaten the industry leaders & their treatment centers/billions/side-effect-riddled SOC.
Godspeed to the researchers and patients and EU/EMA/AU regulators in our trials.
Will be interesting to see if the BP-beholden Congress/FDA will display leadership & respond quickly and favorably (given our excellent safety record and positive RWE reported by our ph2a patients) if our PDD/Rett trials meet or exceed primary endpoints in the coming 3-4 months.
CNS disease-afflicted patients deserve better treatment options and fewer serious side-effects than the current SOC.
GLTAL
[https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/congress-big-pharma-money-123757664.html “I’m really much more concerned because Congress is supposed to have oversight for the FDA,” Brown said. “If the FDA isn’t going to hold pharma accountable, and Congress is getting paid to not hold pharma accountable, then it really doesn’t matter who the president is because it’s really about Congress.”]